TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a leader in novel serotonergic psychedelic drug development committed to innovating proprietary therapeutic solutions for mental health conditions, announced today that the Company’s President and CEO, Mr. Greg Mayes, will participate on a panel at this year’s Horizons…


Previous articleCOMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
Next articleatai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD